Literature DB >> 22471719

In vitro targeted imaging and delivery of camptothecin using cetuximab-conjugated multifunctional PLGA-ZnS nanoparticles.

Veerasikku Gopal Deepagan1, Bruno Sarmento, Deepthy Menon, Ana Nascimento, Aswathy Jayasree, Maya Sreeranganathan, Manzoor Koyakutty, Shantikumar V Nair, Jayakumar Rangasamy.   

Abstract

BACKGROUND: Targeted cancer therapy has been extensively developed to improve the quality of treatment by reducing the systemic exposure of cytotoxic drug. Polymeric nanoparticles with conjugated targeting agents are widely investigated because they offer tunability in particle size, drug release profile and biocompatibility. MATERIALS &
METHODS: Here, we have prepared targeted multifunctional nanoparticles composed of a poly(lactic-co-glycolic acid) matrix, ZnS:Mn(2+) quantum dots and camptothecin, and targeted them to EGF receptor overexpressing cells with a cetuximab antibody.
RESULTS: Physicochemical characterization of multifunctional nanoparticles showed stable particles with sizes of <200 nm. In vitro drug release and blood contact studies showed a sustained release profile, with limited hemolysis. In vitro cytotoxicity and cell uptake studies were carried out in A549, KB and MFC-7 cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, FACS, fluorescent microscopic images and spectroflourimetry.
CONCLUSION: Our studies revealed higher camptothecin activity and uptake in cell lines that overexpress the EGF receptor. All these results suggest that anti-EGF receptor cetuximab-conjugated poly(lactic-co-glycolic acid) multifunctional nanoparticles can be used as a potential nanomedicine against cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22471719     DOI: 10.2217/nnm.11.139

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  8 in total

1.  Use of single chain antibody derivatives for targeted drug delivery.

Authors:  Yaghoub Safdari; Vahideh Ahmadzadeh; Masoumeh Khalili; Hossein Zarei Jaliani; Vahid Zarei; Vahid Erfani-Moghadam
Journal:  Mol Med       Date:  2016-04-22       Impact factor: 6.354

Review 2.  Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.

Authors:  Mostafa Akbarzadeh Khiavi; Azam Safary; Jaleh Barar; Amir Ajoolabady; Mohammad Hossein Somi; Yadollah Omidi
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

Review 3.  The smart targeting of nanoparticles.

Authors:  Adam D Friedman; Sarah E Claypool; Rihe Liu
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 4.  Cancer active targeting by nanoparticles: a comprehensive review of literature.

Authors:  Remon Bazak; Mohamad Houri; Samar El Achy; Serag Kamel; Tamer Refaat
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-09       Impact factor: 4.553

5.  Synthesis and Characterization of Placental Chondroitin Sulfate A (plCSA)-Targeting Lipid-Polymer Nanoparticles.

Authors:  Baozhen Zhang; Mingbin Zheng; Lintao Cai; Xiujun Fan
Journal:  J Vis Exp       Date:  2018-09-18       Impact factor: 1.355

6.  Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours.

Authors:  William J McDaid; Michelle K Greene; Michael C Johnston; Ellen Pollheimer; Peter Smyth; Kirsty McLaughlin; Sandra Van Schaeybroeck; Robert M Straubinger; Daniel B Longley; Christopher J Scott
Journal:  Nanoscale       Date:  2019-10-18       Impact factor: 7.790

7.  Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids.

Authors:  Jian-Ming Lü; Zhengdong Liang; Dongliang Liu; Bin Zhan; Qizhi Yao; Changyi Chen
Journal:  Pharmaceuticals (Basel)       Date:  2021-08-25

Review 8.  The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting.

Authors:  Meng Sun; Ting Wang; Leijiao Li; Xiangyang Li; Yutong Zhai; Jiantao Zhang; Wenliang Li
Journal:  Front Pharmacol       Date:  2021-07-12       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.